PALI PALISADE BIO INC

Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference

Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference

Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET

Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PALI), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that of Palisade Bio will participate at the on Wednesday, October 25, 2023 at 2:00 PM ET.

The "Ask the CEO" conference is intended to provide the investment community with access to ask their questions directly to management. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event through . Participating companies will answer as many questions as possible during the event.

A of the presentation will be available on the page of the section of the Company’s website (). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Palisade Bio 

Palisade Bio is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to .

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

833-475-8247



EN
11/10/2023

Underlying

PALIPALISADE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALISADE BIO INC

 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Co...

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 subjects supports differentiated, colon-targeted PDE4 approach Translational analyses confirm local suppression of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling in colon tissue with minimal peripheral immune modulati...

February 23, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Versto...

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon...

February 17, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets...

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that , will participate in a virtual fireside chat at the Piper Sandler Virtual N...

February 9, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life...

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET Access the webcast Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that , will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in ...

February 5, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Birou...

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design Appointments strengthen Palisade Bio’s clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn’s disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisad...

January 29, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch